To analyze the characteristics of roxadustat utilization in our hospital's renal division, promote rational use of roxadustat, and provide evidence for a post-marketing study.
A retrospective study was conducted. The clinical data of hospitalized patients treated with roxadustat from July 1st, 2021, to June 30th, 2022, in the renal division of our hospital were collected and analyzed.
A total of 208 medical records were included. Twenty-two (10.6%) acute kidney injury patients with anemia without the diagnosis of chronic kidney disease were treated with roxadustat. The average single dose of dialysis patients was significantly higher than that of non-dialysis patients (77.85 vs 67.37 mg, P=0.03). Sixty-three patients (30.3%) received statins, and 27 (13.0%) received sevelamer. There was significant difference between hemoglobin levels at baseline and discharge (84.80 vs 89.43 g·L-1, P=0.007). No adverse events occurred in any patient.
The tolerability and safety were good in anemia patients in the renal division who were treated with roxadustat. However, there existed a few problems, such as off-label drug use, subtherapeutic dosage and drug-drug interactions. It is necessary to strengthen the intervention of clinical pharmacists and promote the rational use of roxadustat.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |